Hypobetalipoproteinemia: Difference between revisions

Jump to navigation Jump to search
Line 44: Line 44:


Normotriglyceridemic hypobetalipoproteinemia, formally called normotriglyceridemic abetalipoproteinemia, is a condition characterized by absence of LDLs and apoB100 and normal triglyceride-rich lipoproteins.<ref name="pmid2909827">{{cite journal| author=Harano Y, Kojima H, Nakano T, Harada M, Kashiwagi A, Nakajima Y et al.| title=Homozygous hypobetalipoproteinemia with spared chylomicron formation. | journal=Metabolism | year= 1989 | volume= 38 | issue= 1 | pages= 1-7 | pmid=2909827 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2909827  }} </ref><ref name="pmid4031057">{{cite journal| author=Herbert PN, Hyams JS, Bernier DN, Berman MM, Saritelli AL, Lynch KM et al.| title=Apolipoprotein B-100 deficiency. Intestinal steatosis despite apolipoprotein B-48 synthesis. | journal=J Clin Invest | year= 1985 | volume= 76 | issue= 2 | pages= 403-12 | pmid=4031057 | doi=10.1172/JCI111986 | pmc=PMC423826 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=4031057  }} </ref>
Normotriglyceridemic hypobetalipoproteinemia, formally called normotriglyceridemic abetalipoproteinemia, is a condition characterized by absence of LDLs and apoB100 and normal triglyceride-rich lipoproteins.<ref name="pmid2909827">{{cite journal| author=Harano Y, Kojima H, Nakano T, Harada M, Kashiwagi A, Nakajima Y et al.| title=Homozygous hypobetalipoproteinemia with spared chylomicron formation. | journal=Metabolism | year= 1989 | volume= 38 | issue= 1 | pages= 1-7 | pmid=2909827 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2909827  }} </ref><ref name="pmid4031057">{{cite journal| author=Herbert PN, Hyams JS, Bernier DN, Berman MM, Saritelli AL, Lynch KM et al.| title=Apolipoprotein B-100 deficiency. Intestinal steatosis despite apolipoprotein B-48 synthesis. | journal=J Clin Invest | year= 1985 | volume= 76 | issue= 2 | pages= 403-12 | pmid=4031057 | doi=10.1172/JCI111986 | pmc=PMC423826 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=4031057  }} </ref>
<ref name="pmid164511">{{cite journal| author=Biemer JJ, McCammon RE| title=The genetic relationship of abetalipoproteinemia and hypobetalipoproteinemia: a report of the occurence of both diseases within the same family. | journal=J Lab Clin Med | year= 1975 | volume= 85 | issue= 4 | pages= 556-65 | pmid=164511 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=164511  }} </ref>


==References==
==References==

Revision as of 18:26, 4 November 2016

WikiDoc Resources for Hypobetalipoproteinemia

Articles

Most recent articles on Hypobetalipoproteinemia

Most cited articles on Hypobetalipoproteinemia

Review articles on Hypobetalipoproteinemia

Articles on Hypobetalipoproteinemia in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Hypobetalipoproteinemia

Images of Hypobetalipoproteinemia

Photos of Hypobetalipoproteinemia

Podcasts & MP3s on Hypobetalipoproteinemia

Videos on Hypobetalipoproteinemia

Evidence Based Medicine

Cochrane Collaboration on Hypobetalipoproteinemia

Bandolier on Hypobetalipoproteinemia

TRIP on Hypobetalipoproteinemia

Clinical Trials

Ongoing Trials on Hypobetalipoproteinemia at Clinical Trials.gov

Trial results on Hypobetalipoproteinemia

Clinical Trials on Hypobetalipoproteinemia at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Hypobetalipoproteinemia

NICE Guidance on Hypobetalipoproteinemia

NHS PRODIGY Guidance

FDA on Hypobetalipoproteinemia

CDC on Hypobetalipoproteinemia

Books

Books on Hypobetalipoproteinemia

News

Hypobetalipoproteinemia in the news

Be alerted to news on Hypobetalipoproteinemia

News trends on Hypobetalipoproteinemia

Commentary

Blogs on Hypobetalipoproteinemia

Definitions

Definitions of Hypobetalipoproteinemia

Patient Resources / Community

Patient resources on Hypobetalipoproteinemia

Discussion groups on Hypobetalipoproteinemia

Patient Handouts on Hypobetalipoproteinemia

Directions to Hospitals Treating Hypobetalipoproteinemia

Risk calculators and risk factors for Hypobetalipoproteinemia

Healthcare Provider Resources

Symptoms of Hypobetalipoproteinemia

Causes & Risk Factors for Hypobetalipoproteinemia

Diagnostic studies for Hypobetalipoproteinemia

Treatment of Hypobetalipoproteinemia

Continuing Medical Education (CME)

CME Programs on Hypobetalipoproteinemia

International

Hypobetalipoproteinemia en Espanol

Hypobetalipoproteinemia en Francais

Business

Hypobetalipoproteinemia in the Marketplace

Patents on Hypobetalipoproteinemia

Experimental / Informatics

List of terms related to Hypobetalipoproteinemia

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Aravind Kuchkuntla, M.B.B.S[2]

Synonyms and keywords: Familial hypobetalipoproteinemia, FHBL, normotriglyceridemic hypobetalipoproteinemia

Overview

FHBL; OMIM 107730, OMIM 615558

Historical Perspective

Pathophysiology

Pathogenesis

Genetics

  • Mutation in the APOB gene (107730) on chromosome 2p24.
  • Familial hypobetalipoproteinemia-2 (FHBL2; 605019) is caused by mutation in the ANGPTL3 gene (604774) on chromosome 1p31.

Natural History, complications and Prognosis

Diagnosis

History and Physical

Laboratory Results

Treatment=

Medical Therapy

Surgical Therapy

Prevention

Hypobetalipoproteinemia is a rare autosomal dominant genetic disorder causing abnormally low levels of LDL cholesterol and apolipoprotein B.[1] It is thought to be caused by a mutation in apolipoprotein B.[2] The patient can have low LDL level and simultaneously have high levels of HDL cholesterol. Typically in hypobtalipoproteinemia, plasma cholesterol levels will be around 80-120 mg/dL, LDL cholesterol will be around 50-80 mg/dL, and longevity can be expected with good nutrition. Affected individuals can be either homozygous or heterozygous, the latter being most commonly asymptomatic.[2]


Normotriglyceridemic hypobetalipoproteinemia, formally called normotriglyceridemic abetalipoproteinemia, is a condition characterized by absence of LDLs and apoB100 and normal triglyceride-rich lipoproteins.[3][4]


[5]


References

  1. Musunuru K, Pirruccello JP, Do R, Peloso GM, Guiducci C, Sougnez C; et al. (2010). "Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia". N Engl J Med. 363 (23): 2220–7. doi:10.1056/NEJMoa1002926. PMC 3008575. PMID 20942659.
  2. 2.0 2.1 Schonfeld G, Lin X, Yue P (2005). "Familial hypobetalipoproteinemia: genetics and metabolism". Cell Mol Life Sci. 62 (12): 1372–8. doi:10.1007/s00018-005-4473-0. PMID 15818469.
  3. Harano Y, Kojima H, Nakano T, Harada M, Kashiwagi A, Nakajima Y; et al. (1989). "Homozygous hypobetalipoproteinemia with spared chylomicron formation". Metabolism. 38 (1): 1–7. PMID 2909827.
  4. Herbert PN, Hyams JS, Bernier DN, Berman MM, Saritelli AL, Lynch KM; et al. (1985). "Apolipoprotein B-100 deficiency. Intestinal steatosis despite apolipoprotein B-48 synthesis". J Clin Invest. 76 (2): 403–12. doi:10.1172/JCI111986. PMC 423826. PMID 4031057.
  5. Biemer JJ, McCammon RE (1975). "The genetic relationship of abetalipoproteinemia and hypobetalipoproteinemia: a report of the occurence of both diseases within the same family". J Lab Clin Med. 85 (4): 556–65. PMID 164511.

Template:WikiDoc Sources Template:WH